Published in Cell Mol Life Sci on February 14, 2010
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis (2010) 0.97
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med (2012) 0.91
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep (2015) 0.85
The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci (2009) 1.62
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 2.89
Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed (2006) 2.57
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology (2005) 1.94
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Isolation of endothelial cells from fresh tissues. Nat Protoc (2008) 1.49
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem (2008) 1.37
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res (2003) 1.37
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol (2008) 1.33
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol (2003) 1.33
Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer (2010) 1.31
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab (2004) 1.28
Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood (2007) 1.24
Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res (2004) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res (2003) 1.22
RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J (2010) 1.21
Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res (2007) 1.20
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials (2009) 1.15
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta (2010) 1.12
Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed (2006) 1.11
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta (2006) 1.11
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother (2007) 1.08
Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res (2013) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2004) 1.06
Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol (2006) 1.05
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis (2010) 1.05
Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther (2006) 1.04
NF-kappa B: a new player in angiostatic therapy. Angiogenesis (2008) 1.04
Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst (2006) 1.03
Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett (2003) 1.03
Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem (2003) 1.02
Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: preliminary human studies. Lasers Surg Med (2002) 1.01
Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res (2007) 1.01
Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res (2004) 0.98
Angiostatic activity of the antitumor cytokine interleukin-21. Blood (2008) 0.98
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg (2012) 0.98
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis (2010) 0.97
Indocyanine green as a prospective sensitizer for photodynamic therapy of melanomas. Acta Biochim Pol (2002) 0.97
Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med (2012) 0.97
In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy. J Med Chem (2010) 0.97
In vivo autofluorescence imaging of early cancers in the human tracheobronchial tree with a spectrally optimized system. J Biomed Opt (2003) 0.97
Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun (2007) 0.96
CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis (2012) 0.96
In vivo time-resolved spectroscopy of the human bronchial early cancer autofluorescence. J Biomed Opt (2009) 0.95
Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat (2012) 0.95
Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer. Int J Radiat Oncol Biol Phys (2006) 0.95
Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev (2013) 0.95
MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochim Biophys Acta (2009) 0.95
The neovessel occlusion efficacy of 15-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy. Photochem Photobiol (2010) 0.94
Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res (2009) 0.93
Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta (2013) 0.93
Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res (2004) 0.93
Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 0.92
Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia (2008) 0.92
Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release (2011) 0.92
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med (2012) 0.91
A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. Biochem Biophys Res Commun (2008) 0.91
Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril (2005) 0.91
Blue-violet excited autofluorescence spectroscopy and imaging of normal and cancerous human bronchial tissue after formalin fixation. Photochem Photobiol (2007) 0.90
In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta (2005) 0.90
Like a bolt from the blue: phthalocyanines in biomedical optics. Molecules (2011) 0.89
Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J (2003) 0.89
Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem (2011) 0.89
Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer (2003) 0.89
Tumor endothelium is characterized by a matrix remodeling signature. Front Biosci (Schol Ed) (2009) 0.88